Abstract

Background: Patients with differentiated thyroid cancer (DTC) are usually managed with total thyroidectomy and subsequent radioiodine ablation of the remnant thyroid tissue. L-thyroxine (L-T4) therapy (about 2 µg/kg) is required for life, with a wide variation in patient dose requirements. The iodothyronine deiodinase types I, II, and III ( DIO1 , DIO2, and DIO3 , respectively) regulate the activity of the thyroid hormone via removal of specific iodine moieties from the precursor molecule T4. During LT4 replacement, the active hormone triiodothyronine (T3) levels strictly depend on DIO2

Year of Publication
2019
Journal
Journal of the National Comprehensive Cancer Network
Volume
17
Issue
3.5
Number of Pages
CGE19 - 062
Date Published
2019
ISBN Number
1540-1405, 1540-1413
URL
https://jnccn.org/view/journals/jnccn/17/3.5/article-pCGE19-062.xml

CGE19-062: The Rs1388378 Polymorphism in the Human DIO2 Gene is Associated with Decreased L-Thyroxine Dose Requirement in Thyroidectomized Patients

17-10-2020

Vice Dean, Female College of Medicine. Associate Professor of Pharmacology

Citation: CGE19-062: The Rs1388378 Polymorphism in the Human DIO2 Gene is Associated with Decreased L-Thyroxine Dose Requirement in Thyroidectomized Patients. Journal of the National Comprehensive Cancer Network. 2019;17(3.5):CGE19 - 062. https://jnccn.org/view/journals/jnccn/17/3.5/article-pCGE19-062.xml.

In: Journal of the National Comprehensive Cancer Network

Published by: , 2019

Cited by: